探索阿尔多缩酶抑制剂作为糖尿病相关残疾的有前途的治疗点
Saheem Ahmad1, Mohammad Faizan Ali Ahmad2, Saif Khan3
1Department of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Hail, 2440, Saudi Arabia.
International journal of biological macromolecules
|September 21, 2024
概括
本综述探讨了阿尔多缩酶抑制剂 (ARI) 作为糖尿病并发症的有前途治疗方法. 开发有效的ARI面临挑战,但有可能显著改善患者的治疗结果并减少与糖尿病相关的死亡率.
科学领域:
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
- 糖尿病学 糖尿病学
背景情况:
- 糖尿病会导致严重的并发症,如神经病变,病,视网膜病变和白内障.
- 涉及阿尔多减少酶 (AR) 的多途径是管理这些糖尿病并发症的关键目标.
- 阿尔多减少酶 (AR) 在二次糖尿病并发症的病理生理学中发挥着关键作用.
研究的目的:
- 审查天然和合成阿尔多缩酶抑制剂 (ARI) 的发展.
- 讨论最近通过ARI治疗糖尿病并发症的进展.
- 突出临床应用ARI开发的挑战和未来方向.
主要方法:
- 关于天然和合成阿尔多缩酶抑制剂 (ARI) 的文献综述.
- 分析阿尔多减少酶 (AR) 在聚醇途径和糖尿病并发症中的作用.
- 检查ARIs的结构特征和药物特异性.
主要成果:
- 阿尔多斯减少酶抑制剂 (ARI) 在缓解糖尿病并发症方面表现有前途.
- 在ARI研究中的新进展提供了潜在的治疗策略.
- 由于疾病变异性和AR复杂性,在将临床前ARI成功转化为临床有效性方面仍然存在重大挑战.
结论:
- 针对性地开发特定的阿尔多减少酶抑制剂 (ARIs) 对于有效治疗糖尿病并发症至关重要.
- 克服ARI特异性和临床翻译方面的挑战可能会彻底改变糖尿病护理.
- 对AR结构和功能的进一步研究对于推进基于ARI的疗法至关重要.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167
Oral Hypoglycemic Agents: Biguanides and Glitazones
182
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
182
Glucagon-like Receptor Agonists
305
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
305
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K


